Medications often branded as Algist contain active ingredients classified as antihistamines, which are generally indicated for the temporary relief of symptoms associated with allergic conditions. This class of drug is used to help address the symptoms that result from histamine release, which may lead to uncomfortable physical responses.

The drug class associated with Algist is utilized within therapeutic areas including allergic rhinitis, allergic conjunctivitis, and various dermatological reactions. Specifically, these medications assist in providing relief for symptoms such as sneezing, a runny nose, itchy/watery eyes, nasal congestion, and skin itching or hives (urticaria).

Managing these symptoms is designed to assist in supporting the patient's comfort and regular daily activities. Managing symptoms, particularly those occurring at night, may assist some individuals in obtaining rest. Beyond allergies, some formulations may be used to help address symptoms related to motion sickness.

Quick Fact: Primarily used for Seasonal and Perennial Allergy Symptoms

Regulatory References

1. NIH MedlinePlus overview on Antihistamines for Allergies

Eligibility Map: Who can and cannot use Algist — Official Regulatory Information

The eligibility status for Algist is strictly defined by regulatory documents, primarily due to the fixed-dose combination of Acetaminophen, a decongestant (Phenylephrine), and a first-generation antihistamine (Chlorpheniramine).

Eligibility Scope	Regulatory Status Basis
Populations for whom use is allowed	Adults and adolescents, generally 12 years of age and older, without listed contraindications.
Populations for whom use is not recommended	Children under 12 years of age, pregnant women, and breastfeeding mothers.
Populations for whom use is contraindicated	Patients with known hypersensitivity to any component, severe coronary artery disease, severe hypertension, or severe hepatic impairment.

Age-Related Eligibility Rules

• Pediatric Use: Use is not recommended or contraindicated in children under 12 years of age.
• Older Adults (Geriatric): Use requires caution due to increased susceptibility to effects like drowsiness and confusion.

Condition-Specific Eligibility Rules

Use is contraindicated in patients with severe liver disease and in individuals currently taking or having recently discontinued Monoamine Oxidase Inhibitors (MAOIs) (within 14 days). Caution is required for patients with diabetes mellitus, hyperthyroidism, glaucoma (narrow-angle), prostatic hypertrophy, or pre-existing mild to moderate kidney or liver impairment.

Connection to the overall eligibility profile: Official regulatory documents establish formal exclusions, prohibiting use in groups with severe cardiac or organ disease and restricting use based on age thresholds and concurrent medication use. The label mandates that this medicine must not be taken with other products containing paracetamol.

The regulatory documentation for Algist establishes multiple categories of official interaction patterns involving its four active components.

Co-administration is strictly contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including certain antidepressants, due to the documented risk of a severe hypertensive reaction. A mandatory separation rule requires a minimum of a two-week waiting period after stopping an MAOI before Algist can be taken. The use of Algist is also prohibited with any other medicinal product containing acetaminophen to prevent exceeding the documented maximum daily dose.

Pharmacodynamic interactions result in additive effects when Algist is combined with other central nervous system (CNS) depressants, such as alcohol, anxiolytics, or hypnotics, officially leading to increased sedation. Other noted pharmacodynamic constraints involve the Phenylephrine component: combination with Digoxin or related cardiac glycosides is linked to a documented risk of irregular heartbeat, and co-administration with Ergot Alkaloids increases the risk of ergotism.

Interactions affecting drug exposure include Metoclopramide and Domperidone, which are documented to increase the speed of acetaminophen absorption, while Cholestyramine reduces its absorption rate. Additionally, a metabolic interaction is noted where the Chlorpheniramine component may inhibit the metabolism of Phenytoin. A population-specific consideration noted in labeling is the increased risk of acetaminophen-related liver damage documented for chronic alcohol abusers.

How Algist Works

Targeting Key Enzymes in the Digestive Tract

Algist exerts its primary action by working as a reversible inhibitor specifically targeting gastrointestinal lipases—the enzymes responsible for breaking down triglycerides in the diet. This mechanism is localized entirely to the lumen of the small intestine, and Algist is largely unabsorbed into the systemic circulation. This domain covers the core biological target and the spatial restriction of the drug's activity.

Consequence of Enzyme Inhibition on Fat Absorption

By binding to the lipases, Algist prevents them from hydrolyzing triglycerides (fat molecules) into smaller, absorbable components like free fatty acids and monoglycerides. This mechanistic cascade results in the passage of a significant portion of undigested fat through the GI tract. The physiological consequence is a direct and quantifiable reduction in the body's absorption of calories derived from fat, which is the mechanism's terminal physiological consequence.

The administration of Algist, a Fixed-Dose Combination (FDC) medicine, is governed by protocols established to standardize its use. The approved and exclusive route of administration is oral, available in solid forms (tablet or capsule) and liquid solutions.

General Dosing and Frequency

Algist is intended for use as needed (PRN), not as a continuous maintenance medication. The standard single dose for adults and children 12 years and older is one unit (tablet or capsule). This dose may be repeated every 4 to 6 hours based on the persistence of symptoms. A core constraint is that the total intake must not exceed six units within any 24-hour period. This maximum limit is partly determined by the total allowable daily consumption of the active analgesic component, Acetaminophen.

Specific Use Conditions and Duration

Standard administration protocols specify that the medicine should be used for short-term courses only, and administration should typically not continue for longer than seven consecutive days. For the liquid formulation, accurate administration requires the use of a calibrated measuring device to ensure precise dosing. The use of Algist is permitted with or without food.

Age-Based Adjustments

Standard protocols include specific adjustments for pediatric patients. Children between the ages of 6 and 11 years are directed to use a reduced dose of one-half unit every 4 to 6 hours, with a maximum limit of three units in 24 hours.

Research Evidence / Overview of Studies for Algist

This overview describes the types of clinical studies conducted on Algist, a fixed-dose combination medicine, detailing what research has explored and where evidence remains limited, according to regulatory and scientific sources.

---

Evidence for Multisymptom Relief in Common Cold and Flu-like Manifestations

Research into this combination medicine primarily involves short-term Randomized Controlled Trials (RCTs) and Systematic Reviews used in research exploring how symptoms change over time. The populations studied were mainly adults and older adolescents experiencing acute, self-limiting symptoms consistent with the common cold or flu. The evidence contributes to understanding symptom patterns, focusing on outcomes related to physical discomfort and outcomes describing episodic or acute changes in symptoms such as fever, congestion, and headache. Findings describe patterns observed in the studies, and research explored whether the combined components were associated with changes in symptom severity in the short term.

However, follow-up durations were limited, and existing studies provide limited insight into outcomes beyond the acute illness episode. Evidence quality varies across studies, and data for certain groups, such as those with pre-existing health issues, remain insufficient.

Evidence for Temporary Relief of Allergic Rhinitis Symptoms

Algist was also studied for conditions characterized by fluctuating manifestations, such as allergic rhinitis (hay fever). Research examined the component antihistamine and decongestant in trials assessing short-term symptom patterns, focusing on outcomes capturing phases of heightened symptom activity, including sneezing frequency, itchy eyes, and nasal blockage.

Research highlights changes measured during the study period, consistent with the patterns of short-term change that was observed in research for these classes of medicines. A key limitation is that evidence often relies on the established profile of the individual component drugs rather than dedicated trials of the complete four-ingredient combination specifically for allergy symptoms alone.

Duration of Follow-up and Remaining Uncertainties

Most RCTs monitored responses over defined time intervals, typically up to one week. As a result, long-term effects are not well characterized. Research provides context but not individual predictions about symptom patterns beyond the acute phase of illness.

Comparative evidence is limited for the precise contributions of the full four-ingredient combination when examined against dual or triple combinations. A significant uncertainty involves the orally administered decongestant component (Phenylephrine), where studies have explored its systemic absorption and associated symptom changes, and which remains an area of ongoing research and regulatory evaluation.

Common questions about Algist (FAQ)

Q: What is Algist mainly used for, in simple terms?

A: According to official regulatory documents, Algist is described as being indicated for the temporary relief of multiple symptoms linked to the common cold, flu-like illnesses, and allergic rhinitis.

These symptoms typically include fever, nasal congestion, headache, and sneezing.

Q: What is the main ingredient in Algist?

A: Algist is officially described as a Fixed-Dose Combination (FDC) medicine, which means it contains four active components.

The ingredients listed include Acetaminophen, Chlorpheniramine, and Phenylephrine, which are included to achieve the intended temporary relief of symptoms described in the official indications.

Q: How quickly should Algist start making a difference?

A: The regulatory documentation contains detailed information about how long it takes for the active components to reach their peak concentration in the body.

However, the time an individual patient notices relief from their symptoms can vary.

Q: Are there common signs that Algist is working for me?

A: The intended effects described in the drug’s approved indications include the temporary relief of targeted symptoms.

These specific effects include a reduction in fever, congestion, headache, and sneezing frequency.

Q: Is it normal to feel a bit tired when first taking Algist?

A: Drowsiness is a documented side effect associated with one of the active ingredients in Algist.

This effect is listed in the official safety information under nervous system disorders.

Q: Can Algist affect my ability to drive or operate machinery?

A: The product labeling includes a specific warning that Algist may cause drowsiness or dizziness.

Because of this potential effect, the regulatory product labeling contains a warning that caution is required when operating machinery or driving a motor vehicle.

Q: Does Algist affect sleep patterns?

A: Drowsiness is a reported side effect of Algist, which may consequently affect sleep patterns.

The official product label includes a specific warning about the product's potential to cause drowsiness.

Q: What is the risk of Algist causing an allergic reaction?

A: Serious hypersensitivity reactions, including anaphylaxis, have been reported in the postmarketing setting.

Official safety information requires the medication to be immediately discontinued if signs of a serious reaction are suspected.

Q: Are the side effects of Algist permanent?

A: Common adverse reactions are generally described as transient, meaning they are temporary.

The serious adverse effects reported, such as severe liver injury or acute kidney injury, are documented in regulatory reports as having serious long-term consequences.

Q: What should I do if the side effects of Algist feel too strong?

A: The safety information requires immediate discontinuation of the drug if signs of severe liver injury or a serious hypersensitivity reaction are suspected.

For common, transient side effects that are bothersome, regulatory documents indicate a healthcare professional should be consulted.

Q: What are the major reasons someone should not take Algist?

A: Official labeling establishes strict contraindications for Algist.

Official documents list major contraindications, such as the simultaneous use of Monoamine Oxidase Inhibitors (MAOIs), use of any other medicine containing acetaminophen, and a history of severe hepatic (liver) impairment.

Q: Can I use Algist if I have high blood pressure?

A: The product labeling requires individuals with pre-existing conditions, including high blood pressure, to consult a healthcare provider before use.

Q: Does Algist have any effect on blood sugar levels?

A: The product labeling includes a requirement for individuals with conditions such as diabetes to consult a healthcare provider prior to use.

This caution relates to the potential effects of certain components on underlying health conditions.

Q: Can Algist be used by people with kidney problems?

A: The regulatory labeling notes that caution is required for individuals with pre-existing kidney problems.

Acute Kidney Injury (AKI) has been reported in rare cases, and the official information indicates a healthcare provider should be consulted by patients with kidney impairment.

Q: Can I take Algist if I have a history of liver issues?

A: Algist is strictly contraindicated for individuals with severe hepatic (liver) impairment.

Official warnings also highlight that chronic alcohol abusers have an increased risk of acetaminophen-related liver damage.

Q: Are people with [general mental health condition] eligible to use Algist?

A: Use of Algist is strictly contraindicated with Monoamine Oxidase Inhibitors (MAOIs), which include certain types of antidepressants.

Official regulatory documents define a required separation period between stopping an MAOI and starting Algist.

Q: Is Algist safe for elderly patients?

A: The regulatory labeling notes that caution and careful monitoring may be required when Algist is administered to elderly patients.

This is due to the elderly population’s potential for increased sensitivity to the effects of the active ingredients.

Q: Can Algist be used during pregnancy or while breastfeeding?

A: Regulatory documentation describes the risk assessment that must be made for use during pregnancy, requiring the potential benefit to justify the risk to the fetus.

It also cautions that components of the drug are known to be excreted into breast milk.

Q: Why does the packaging say Algist has a Black Box Warning?

A: The Boxed Warning is a regulatory requirement included to highlight the most serious documented risk associated with the medication.

For Algist, this warning specifically addresses the risk of severe liver injury.

Q: Is Algist addictive or habit-forming?

A: Algist is not classified as a controlled substance by regulatory agencies.

Therefore, it is not considered to be addictive or habit-forming.

Q: Is it okay to stop taking Algist suddenly?

A: As Algist is intended for short-term, as-needed (PRN) use, the discontinuation instructions do not typically include a requirement for tapering the dose.

Q: Do I need a special blood test while taking Algist?

A: Routine blood tests are not typically required for all patients during the course of treatment.

However, the regulatory label specifies that obtaining appropriate liver function tests is required if liver injury is suspected.

Q: Are there any specific foods or drinks to avoid while using Algist?

A: The official product information includes a warning about consuming alcoholic drinks while using Algist.

This is due to the potential for increased sedation and other additive effects on the central nervous system.

Q: How long does Algist stay in your system after stopping?

A: The regulatory documentation includes information regarding the half-life of the active components.

The exact time it takes for the medicine to be fully cleared from the body is dependent on individual metabolic factors.

Q: Is there a generic version of Algist available?

A: The availability of generic versions of Algist is officially tracked in regulatory databases.

Information on product status can be found in resources such as the FDA Orange Book.

Q: Why are there different strengths of Algist available?

A: Multiple strengths are manufactured to provide appropriate dosing options for the specific patient populations defined in the regulatory documentation.

This includes having different formulations for adults versus pediatric patients.

Q: Do studies show Algist is more helpful for certain age groups?

A: Clinical studies of Algist primarily focused on adults and older adolescents.

The documented results reflect the effectiveness patterns observed within those specific study populations.

Q: What is the difference between Algist and a placebo in studies?

A: The Clinical Studies section of the regulatory documentation summarizes the findings of randomized controlled trials (RCTs).

These findings show that the active ingredients provided statistically significant differences in primary outcomes compared to placebo.

Q: Can Algist be crushed or broken before taking it?

A: The approved drug specifications require that if the solid formulation (tablet or capsule) is not specifically labeled as safe to crush or break, it should be swallowed whole to ensure correct administration.

Q: Is Algist safe to travel with?

A: Official labeling requirements define the storage conditions required to maintain the drug’s stability.

These conditions specify controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), which should be noted when traveling.

How to Store and Dispose of Algist

Algist must be stored according to official labeling requirements to maintain stability and prevent unintentional harm. The medication should be kept at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F), and protected from excessive heat and moisture. The product must remain in its original container, tightly closed, and stored out of the sight and reach of children.

Official Disposal Rules

Unused or expired Algist should be managed via a drug take-back program if one is available. If not, the medication must be rendered unappealing by mixing it with an undesirable substance (such as coffee grounds or dirt) before being placed in a sealed bag and discarded in the household trash. It is explicitly advised not to flush this medication down the sink or toilet.